高度心臓モニタリング装置の世界市場-2023年～2030年

概要

心臓モニタリング装置は、遠隔地から患者の心臓の状態を観察するために、医師/医者が提案する小型装置です。最先端の技術により、この装置は心拍のわずかな潜在的な音や異常さえも検出することができます。これらの小さな不整脈や異常は心臓不整脈と呼ばれます。不整脈が必ず起こる場合は、心臓に問題があり、医療的支援が必要です。

心臓モニタリング装置を使用すれば、重要な心臓の健康情報をすべて観察し、文書化し、すぐに医師に提示することができるため、医務室に何度も足を運ぶ必要がなくなり、ケアユニットが遠隔で心臓の健康を管理することができます。心臓モニタリングのアプローチは、装置が一時的なものか恒久的なものか、またどのような種類のデータを把握する必要があるかによって異なります。

心血管疾患の症例の増加、製品認可の増加、研究活動からの好結果、M&Aを含む市場開拓、製品導入、認知度の向上などが、予測期間における世界の高度心臓モニタリング装置市場の成長を後押しすると予想されます。さらに、新製品の発売や技術の進歩も、予測期間における世界市場の成長に貢献すると期待されています。

ダイナミクス

製品の上市と認可の増加

明確な規制機関からの製品上市と認可は、予測期間中の世界市場の成長を後押しすると予想されます。例えば、2021年2月、Remo Care Solutions社はRemo.Cardiaを発表しました。Cardiaは、人工知能を活用して患者のバイタルをリアルタイムで監視・分析する遠隔心臓モニタリングシステムです。さらに、2021年11月、革新的な遠隔生体情報モニタリング製品の提供に集中する日常的な医療技術企業であるBiotricity Inc.は、医師が利用する正確な常時心臓モニタリング技術を提示する消費者直販の心臓モニターBioheartを発売しました。

さらに2021年7月、アボット社は米国で挿入型心臓モニター（ICM）であるJot Dxを発表しました。この技術は、個人の心臓不整脈の遠隔検出と診断精度の向上を可能にします。同様に、2022年4月、メドトロニックは、欧州でクラウドベースのアップデートにより、LINQ II挿入型心臓モニター（ICM）に使用することを目的とした2つのAccuRhythm AIアルゴリズムを発表しました。AccuRhythm AIは、LINQ IIによって収集された心臓リズムイベントデータに人工知能（AI）を使用し、医療従事者が不規則な心臓リズムを合理的に分析・治療できるように、得られるデータの精度を高めます。

心血管疾患の増加

心血管疾患の症例が増加していることから、予測期間中に高度心臓モニタリング装置の需要が高まると予想されています。例えば、World Heart Foundation Report 2023によると、心血管系疾患（CVD）による死亡者数は1990年の1,210万人から2021年には2,050万人に増加し、全死亡者数の3分の1に近い1億2,100万人です。2021年においても、CVDは世界的に死亡原因のトップであり、CVDによる死亡の5人に4人は中低所得国（LMICs）で起こっています。

さらに、英国心臓財団（British Heart Foundation）の「世界の心臓・循環器疾患ファクトシート2023」によると、世界中で約6億2,000万人が心臓・循環器疾患を患っており、この数はライフスタイルの変化、住民の高齢化、増加、心臓発作や脳卒中による生存率の向上により増加しており、こうした傾向が続けば今後も増加すると推定されます。

さらに、世界全体では、13人に1人が心臓や循環器系の疾患とともに生活していると評価されています。心臓や循環器系の疾患は、世界中で約3人に1人の死因となっており、2021年には推定2,050万人、1日平均5万6,000人、1.5秒に1人の死者が出ると推定されています。オーストラリア政府の保健・高齢者医療省によると、オーストラリアでは心臓血管疾患が死傷者の約27％を占め、約120万人のオーストラリア人が1つ以上の心臓・血管疾患を患っています。

サイバーセキュリティの脅威と規制違反

心臓モニタリング装置に関連するサイバーセキュリティの脅威の存在は、予測期間中の世界市場の成長を妨げると予想されます。例えば、2023年7月、サイバーセキュリティ・インフラセキュリティ庁（CISA）は、医療機器企業メドトロニックの心臓デバイスに極端な脆弱性があることを警告しました。さらに、セキュリティ・アップデートの中で、メドトロニック社は、オプションのメッセージング・エレメントを特定したと宣言しました。

同社は、現在のソフトウェアでこの問題の修正プログラムを作成し、メッセージングエレメントを削除するさらなるソフトウェアアップデートを割り当てた。さらに、規制ガイドライン違反は製品リコールの原因となり、予測期間中の世界市場の成長を鈍化させます。例えば、食品医薬品局（FDA）は、心臓モニタリング企業であるiRhythm IRTC社に対し、同社の開発がFDAのデバイスおよびラベリング規範に違反していると指摘し、通知を行っています。

誤検知アラームの多発

誤検知アラームの頻度の高さも、予測期間中の世界市場の成長を妨げると予想されます。例えば、「Circulation：例えば、"Arrhythmia and Electrophysiology"（不整脈と電気生理学）に掲載された新しいデータによると、心臓の不整脈を追跡するために使用される植え込み型ループレコーダ（ILR）は、誤検知の可能性があります。この論文によれば、この研究では全警報の59.8％が誤検知であり、心房頻拍（AT）/心房細動（AF）AT/AF（74.2％）および心房細動（76.8％）の誤検知率が高くなっています。

さらに、一般的に診療所では、集中治療室（ICU）の患者モニターでは、商標や費用に関係なく、不整脈アラームの誤認率が極めて高いです。このようなアラームの誤配分は、患者の安静を妨げ、病院のリソースを空費し、可能性のある緊急事態に対する診療チームの感覚を鈍らせます。ベッドサイドのモニターが割り当てる生命を脅かす心電図（ECG）アラームの43％は不正確であり、アラームの種類によっては90％にも上ると評価されています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 製品の上市と認可の増加
    • 心血管疾患患者の増加
  • 抑制要因
    • サイバーセキュリティの脅威と規制違反
    • 誤検知アラームの多発
  • 機会
  • 影響分析

第5章 業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• 特許分析
• 技術動向
• エンドユーザー動向
• SWOT分析
• DMIの見解

第6章 COVID-19分析

第7章 デバイスタイプ別

• ECGモニター
• 挿入型心臓モニター
• ホルターモニター
• イベントレコーダー
• モバイル心臓テレメトリー
• スマートウェアラブル
• 植え込み型心臓ループレコーダー
• その他

第8章 適応症別

• 徐脈
• 頻脈
• 心房・心室細動
• その他

第9章 エンドユーザー別

• 病院
• 専門クリニック
• 外来手術センター
• 学術研究機関
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Abbott
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Medtronic plc
• Boston Scientific Corporation
• Biotronic AG
• Stryker
• Microport Scientific Corporation
• Koninklijke Philips N.V.
• Lepu Medical Technology（Beijing）Co., Ltd.
• GE HEALTHCARE
• Nihon Kohden

第13章 付録

Overview

A cardiac monitoring device is a miniature device suggested by the doctor/medic to observe a patient's cardiac state from a distance, remotely. State-of-the-art technology facilitates the device to detect even the slightest potential sounds and abnormalities in the heartbeat. These small irregularities and anomalies are anointed heart arrhythmias. If the arrhythmias transpire invariably, there is an issue in the heart that requires medical assistance.

With a cardiac monitoring device, significant cardiac health information can all be observed, documented, and presented to the physician immediately eliminating the requirement for repeated visits to the medic's office and permitting the care unit to handle the cardiac health remotely. Cardiac monitoring approaches can differ based on whether the device is temporary or permanent and what sort of data needs to be apprehended.

The growing cases of cardiovascular diseases, increasing product authorizations, positive outcomes from research activities, market developments including mergers, acquisitions, product introductions, growing awareness among other factors are expected to boost the global advanced cardiac monitoring devices market growth in the forecast period. Further, the new product launches and technological advancements also expected to contribute to the global market growth in the forecast period.

Dynamics

Increasing Product Launches and Authorizations

The product launches and authorizations from distinct regulatory bodies are expected to boost the global market growth during the forecast period. For instance, in February 2021, Remo Care Solutions introduced Remo. Cardia is a remote cardiac monitoring system that utilizes artificial intelligence to monitor and analyze patients' vitals in real time. Moreover, in November 2021, Biotricity Inc., an everyday medical technology corporation concentrated on providing innovative, remote biometric monitoring products, launched Bioheart, a direct-to-consumer heart monitor that presents the exact constant heart monitoring technology utilized by physicians.

Further, in July 2021 Abbott introduced Jot Dx, the insertable cardiac monitor (ICM) in the United States. This technology permits remote detection and enhanced diagnostic precision of cardiac arrhythmias in individuals. Similarly, in April 2022, Medtronic introduced two AccuRhythm AI algorithms intended to be used for LINQ II insertable cardiac monitors (ICM) via cloud-based updates in Europe. AccuRhythm AI uses artificial intelligence (AI) to heart rhythm event data gathered by LINQ II, enhancing the precision of data medics obtain so they can reasonably analyze and treat irregular heart rhythms.

Growing Cases of Cardiovascular Diseases

The growing cases of cardiovascular diseases are expected to boost the demand for advanced cardiac monitoring devices in the forecast period. For instance, according to the World Heart Foundation Report 2023, deaths from cardiovascular disease (CVD) bounced worldwide from 12.1 million in 1990 to 20.5 million in 2021, near to a third of all deaths and a general growth on the assessed 121 million CVD mortalities. Again, CVD was the top reason of death globally in 2021, with four in five CVD deaths happening in low- and middle-income nations (LMICs).

Moreover, according to the British Heart Foundation's Global Heart & Circulatory Diseases Factsheet 2023, about 620 million individuals are living with cardiac and circulatory conditions across the globe this number has been increasing owing to varying lifestyles, an aging, and growing inhabitants, and enhanced survival rates from heart attacks and strokes and is estimated to persist to increase if these trends persist.

Further, globally it is assessed that 1 in 13 individuals are living with a cardiac or circulatory disorder. Heart and circulatory conditions cause about 1 in 3 deaths worldwide, an estimated 20.5 million casualties in 2021, an average of 56,000 individuals per day, or one death every 1.5 seconds. Again, according to the Department of Health and Aged Care Government of Australia, Cardiovascular conditions cause around 27% of casualties in Australia and about 1.2 million Australians have 1 or more heart or vascular diseases.

Cybersecurity Threats and Violation of Regulations

The presence of cybersecurity threats associated with cardiac monitoring devices is expected to hamper the global market growth during the forecast period. For instance, in July 2023, The Cybersecurity and Infrastructure Security Agency (CISA) alerted of an extreme vulnerability in a cardiac device from medical device corporation Medtronic. Moreover, in a security update, the medtech giant declared that it had pinpointed an optional messaging element that, if allowed, a licensed user could manipulate the flaw, directing to the possible omission, stealing, or transformation of cardiac device data.

The corporation drafted a fix for the problem on the present software and has allocated a further software update that withdraws the messaging element. Furthermore the the violation of regulatory guidelines can cause product recalls slowing the global market growth during the forecast period. For instance, the Food and Drug Administration (FDA) has given a notice to the heart monitoring corporation iRhythm IRTC, noting that its developments enclose breaches of FDA device and labeling norms.

High Frequency of False Positive Alarms

The high frequency of false positive alarms is also expected to hamper the global market growth during the forecast period. For instance, according to new data published in an article titled "Circulation: Arrhythmia and Electrophysiology," the implantable loop recorders (ILR) employed to follow cardiac arrhythmias are liable to false positive alerts, ILRs are typical diagnostic devices for individuals with a potential arrhythmia, permitting for long-term remote patient monitoring. The article concluded that 59.8% of all alerts in the study were wrong, with elevated false-positive rates for atrial tachycardia (AT)/atrial fibrillation (AF)AT/AF (74.2%) and asystole (76.8%) alerts.

Further, typically in infirmaries, false arrhythmia alarm rates are extremely elevated in intensive care units (ICUs) patient monitors irrespective of their trademarks and expenses. These falsely allocated alarms disrupt individuals' rest, empty hospital resources, and desensitize the infirmary team to possible emergencies, anointed as false alarm fatigue. It has been assessed that 43% of life-threatening electrocardiogram (ECG) alarms allocated by bedside monitors are inaccurate, with some types of alarms being as elevated as 90%.

Segment Analysis

The global advanced cardiac monitoring devices market is segmented based on device type, indication, end-user and region.

ECG Monitors Device Type Expected to Dominate Market

With the increase in the ECG monitor product market introductions and market developments in this segment the ECG monitor device type is expected to dominate the global market in the forecast period. For instance, in May 2022, AliveCor introduced the KardiaMobile Card, a credit card-sized, tiniest personal ECG device designed to enhance health outputs and reduce the expense of cardiac therapy. A single-lead ECG of medical quality is produced in 30 seconds via the KardiaMobile Card, which fits comfortably into any wallet.

Moreover, in August 2023, Clario, a healthcare research technology corporation that provides top endpoint technology products for clinical investigations, expanded its partnership with AliveCor, the top leader in FDA-cleared personal electrocardiogram (ECG) technology. This partnership intends to allow trial participants to accumulate medical-grade six-lead ECG readings in the convenience of their residences via KardiaRx, a clinical-trial-focused app.

Geographical Penetration

Growing Cases of Cardiovascular Diseases

Owing to the increasing cases of cardiovascular disease in North America the region is estimated to dominate the global market during the forecast period. For instance, according to the Centers for Disease Control and Prevention, June 2022 update around 20.1 million adults aged 20 and older had coronary heart disease (CAD) in 2020 in the United States. It even noted that coronary heart condition is the highly typical type of heart condition in the United States.

Furthermore, the increase in market developments in this region is also contributing to the regional market growth in the forecast period. For instance, in November 2022, OMRON Healthcare, Co., Ltd., a multinational healthcare corporation, collaborated with Cardio Signal, a U.S.-established health technology corporation, aspired to get innovations in premature cardiovascular condition detection to help clinicians at the forefront of Population Health management.

Similarly, in July 2021, Nihon Kohden Digital Health Solutions Inc., the U.S. regional development associate of Nihon Kohden, completed the acquisition of 100% shares of Advanced Medical Predictive Devices, Diagnostics, and Displays, Inc., following this acquisition, Nihon Kohden's long-term intends to develop innovative healthcare monitoring devices to crack global medical issues and to deliver better future to individuals with from diverse conditions.

COVID-19 Impact Analysis

COVID-19 unexpectedly increased patient safety, prior to the COVID-19 pandemic, patient monitoring for harm and multiple strategies to avert damage were related to where the individuals were treated in the hospital. The challenges raised by the Coronavirus disease 2019 (COVID-19) pandemic to the health service globally directed to a quick transformation of infection condition protocols in-hospital.

Although the integration of technology in the clinical workplace is yet in its babyhood, it has rapidly progressed via the Gartner Hype Cycle for rising technologies and its adoption has additionally quickened after the coronavirus disease 2019 (COVID-19) pandemic and the fierce growth of telehealth. The COVID-19 pandemic has led to an acceleration in healthcare innovation, with the adoption of telemedicine taking residence nearly overnight. Additional wearable patient monitoring devices are used to help improve the availability of monitoring and therapy of patients and to support addressing the deduction of healthcare provider exposure to SARS-CoV-2, especially for people with heart disease.

By Device Type

• ECG Monitors
• Insertable Cardiac Monitor
• Holter Monitor
• Event Recorder
• Mobile cardiac Telemetry
• Smart Wearables
• Implantable Cardiac Loop Recorders
• Others

By Indication

• Bradycardia
• Tachycardia
• Atrial and Ventricular Fibrillation
• Others

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgery Centers
• Academic Research Institutes
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In July 2023, Biotricity Inc., a Technology-as-a-Service (TaaS) corporation functioning in the remote cardiac monitoring domain of consumer healthcare, reinforced connections with Amazon and Google. The company is extending its AI technology development in remote cardiac care, leveraging its proprietary AI technology to deliver a suite of predictive monitoring devices to improve new condition profiling, enhance patient control, and revolutionize the healthcare enterprise for disease precluding.
• In May 2023, Abbott, obtained U.S. Food and Drug Administration (FDA) clearance for its Assert-IQ insertable cardiac monitor (ICM), offering medics a unique choice for diagnostic evaluation and long-term monitoring of individuals experiencing irregular heartbeats.
• In January 2023, Royal Philips, a multinational leader in health technology, and Masimo, a multinational medical technology corporation, expanded their collaboration to increase individual monitoring capacities in-home telehealth applications with the Masimo W1 state-of-the-art health tracking watch. The W1 intends to merge with Philips's enterprise patient monitoring ecosystem to proffer the vanguard of telemonitoring and telehealth.

Competitive Landscape

The major global players in the market include: Abbott, Medtronic plc, Boston Scientific Corporation, Biotronic AG, Stryker, Microport Scientific Corporation, Koninklijke Philips N.V., Lepu Medical Technology (Beijing)Co., Ltd., GE HEALTHCARE, and Nihon Kohden among others.

Why Purchase the Report?

• To visualize the global advanced cardiac monitoring devices market segmentation based on device type, indication, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of advanced cardiac monitoring devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global advanced cardiac monitoring devices market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Device Type
• 3.2. Snippet by Indication
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Product Launches and Authorizations
    • 4.1.1.2. Growing Cases of Cardiovascular Diseases
  • 4.1.2. Restraints
    • 4.1.2.1. Cybersecurity Threats and Violation of Regulations
    • 4.1.2.2. High Frequency of False Positive Alarms
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Patent Analysis
• 5.6. Technology Trend
• 5.7. End-User Trend
• 5.8. SWOT Analysis
• 5.9. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Device Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 7.1.2. Market Attractiveness Index, By Device Type
• 7.2. ECG Monitors*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Insertable Cardiac Monitor
• 7.4. Holter Monitor
• 7.5. Event Recorder
• 7.6. Mobile cardiac Telemetry
• 7.7. Smart Wearables
• 7.8. Implantable Cardiac Loop Recorders
• 7.9. Others

8. By Indication

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 8.1.2. Market Attractiveness Index, By Indication
• 8.2. Bradycardia*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Tachycardia
• 8.4. Atrial and Ventricular Fibrillation
• 8.5. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Specialty Clinics
• 9.4. Ambulatory Surgery Centers
• 9.5. Academic Research Institutes
• 9.6. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Abbott*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Medtronic plc
• 12.3. Boston Scientific Corporation
• 12.4. Biotronic AG
• 12.5. Stryker
• 12.6. Microport Scientific Corporation
• 12.7. Koninklijke Philips N.V.
• 12.8. Lepu Medical Technology (Beijing) Co., Ltd.
• 12.9. GE HEALTHCARE
• 12.10. Nihon Kohden

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us